Literature DB >> 28768936

Comparison of thyroglobulin and thyroid peroxidase antibodies measured by five different kits in autoimmune thyroid diseases.

Eijun Nishihara1, Nobuyuki Amino1, Takumi Kudo1, Mitsuru Ito1, Shuji Fukata1, Mitsushige Nishikawa1, Hirotoshi Nakamura1, Akira Miyauchi1.   

Abstract

It is generally believed that the detection of thyroid peroxidase antibodies (TPOAb) is superior to that of thyroglobulin antibodies (TgAb) for the diagnosis of Hashimoto's thyroiditis. However, limited data are available on the comparison of TgAb and TPOAb prevalence as a diagnostic measurement for Hashimoto's thyroiditis using sensitive immunoassays. We herein used five different current immunoassay kits (A-E) to compare the prevalence of TgAb and TPOAb in Hashimoto's thyroiditis (n = 70), Graves' disease (n = 70), painless thyroiditis (n = 50), and healthy control subjects (n = 100). In patients with Hashimoto's thyroiditis, positive TgAb was significantly more frequent than positive TPOAb in kits A-D (mean ± SD of the four kits: 98.6 ± 1.7 vs 81.4 ± 2.0%). In patients with Graves' disease, TgAb prevalence was almost equivalent to that of TPOAb in five kits. Patients with painless thyroiditis exhibited positive TgAb significantly more frequently than positive TPOAb in kits A-D (73.5 ± 4.1 vs 33.0 ± 3.4%). The prevalence of TgAb alone was significantly higher than that of TPOAb alone in both Hashimoto's thyroiditis and painless thyroiditis in kits A-D. In kit E, TgAb and TPOAb prevalence did not differ significantly for any disease, and TgAb distribution was different from other kits. In conclusion, the prevalence of TgAb was higher than that of TPOAb in patients with Hashimoto's thyroiditis and painless thyroiditis using commercially available kits. We suggest that TgAb immunoassay is the first choice of screening test for thyroid autoimmune abnormalities in Japan.

Entities:  

Keywords:  Hashimoto’s thyroiditis; Thyroglobulin antibodies; Thyroid peroxidase antibodies

Mesh:

Substances:

Year:  2017        PMID: 28768936     DOI: 10.1507/endocrj.EJ17-0164

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  Moderate Frequency of Anti-Thyroglobulin Antibodies in the Early Phase of Subacute Thyroiditis.

Authors:  Eijun Nishihara; Nobuyuki Amino; Takumi Kudo; Kazuyoshi Kohsaka; Mitsuru Ito; Shuji Fukata; Mitsushige Nishikawa; Hirotoshi Nakamura; Akira Miyauchi
Journal:  Eur Thyroid J       Date:  2019-07-15

Review 2.  An update on the pathogenesis of Hashimoto's thyroiditis.

Authors:  A P Weetman
Journal:  J Endocrinol Invest       Date:  2020-12-17       Impact factor: 4.256

3.  A case of thyrotoxicosis-induced anemia in a patient with painless thyroiditis.

Authors:  Ichiro Komiya; Takeaki Tomoyose; Noriharu Yagi; Gen Ouchi; Tamio Wakugami
Journal:  Thyroid Res       Date:  2021-04-23

4.  Case Report: Onset of Type 1 Diabetes Mellitus in a Patient With Ulcerative Colitis and Sjogren's Syndrome Under Euthyroid Hashimoto's Thyroiditis.

Authors:  Kaio Takahashi; Takatoshi Anno; Akio Matsuda; Yukiko Kimura; Fumiko Kawasaki; Kohei Kaku; Koichi Tomoda; Hirofumi Kawamoto; Hideaki Kaneto
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-17       Impact factor: 5.555

5.  Differential Diagnosis of Thyrotoxicosis by Machine Learning Models with Laboratory Findings.

Authors:  Jinyoung Kim; Han-Sang Baek; Jeonghoon Ha; Mee Kyoung Kim; Hyuk-Sang Kwon; Ki-Ho Song; Dong-Jun Lim; Ki-Hyun Baek
Journal:  Diagnostics (Basel)       Date:  2022-06-15

6.  Possible added value of thyroglobulin antibody (TgAb) testing in the evaluation of thyroidal status of subjects with overweight or obesity.

Authors:  P Fierabracci; A Basolo; G Scartabelli; S Bechi Genzano; G Salvetti; G Sotgia; M Rotondi; L Chiovato; G Ceccarini; F Santini
Journal:  J Endocrinol Invest       Date:  2022-07-04       Impact factor: 5.467

7.  Infliximab Therapy Could Decrease the Risk of the Development of Thyroid Disorders in Pediatric Patients With Crohn's Disease.

Authors:  Aleksandra Furtak; Anna Maria Wedrychowicz; Malgorzata Sladek; Andrzej Wedrychowicz; Krzysztof Fyderek; Jerzy Starzyk
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-15       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.